VSEE

SAN JOSE, CA / ACCESS Newswire / April 1, 2026 / VSee Health, Inc. (Nasdaq:VSEE), a leader in AI-powered telehealth technology and high-acuity virtual care solutions, today reported its financial and operational results for the full year ended December 31, 2025. The Company delivered strong top-line growth and meaningful margin improvement while significantly narrowing its net loss. Key Financial Highlights (Year-over-Year Comparisons) Revenue increased 40% to $14,618,184 in 2025 from $10,421,352 in 2024 Gross margin rose 2% to $7,355,965 from $7,177,580 Operating expenses declined sharply by 76% The Company strengthened its balance sheet through multiple debt to equity conversions Cash and liquidity: Cash and cash equivalents increased to $5,266,286 at December 31, 2025, from $326,115 at December 31, 2024 Key Business Highlights During 2025 VSee Health focused on reducing public expenses associated with the IPO, and growth in its telehealth clinical services group. The company derived its 40% revenue growth by targeting large IDN's (Integrated Health Networks) in the USA. The team signed several large scale multi-year contracts (one for $10 million per year previously announced) in early and mid 2025. The telehealth revenue for new large healthcare institutional accounts takes several months to begin, as the operations are complex and must be integrated into VSee heath's technology before rolling out services. This is particularly important for our investors to understand that a majority of 2025 growth was in the second half of the year, and subsequently provides solid future growth in those accounts during 2026 as services continue to roll out to as many as 20 states this fiscal year. Management is bullish for 2026 growth as these contracts are continuing to build revenue and adding additional telehealth services. VSee Health continues to service government accounts such as NASA. In 2025 VSee Labs Inc was nominated and approved for Fedramp High status with the Federal Government as a technology partner. This was achieved through its HHS (Health and Human Services) contract awarded during 2024 and into 2025. VSee continues to pursue several government healthcare related projects in 2026. VSee Health experienced extremely high legal, accounting, and integration expenses associated with the IPO process in 2024 and 2025. The executive team worked diligently wi...

SAN JOSE, CA / ACCESS Newswire / October 17, 2025 / VSee Health, Inc. (Nasdaq:VSEE), a leader in telehealth solutions, reported its financial results for the three months ended June 30, 2025 ("Second Quarter 2025"). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2024 ("Second Quarter 2024"). Highlights Second Quarter 2025 revenue of $3.4 million, up 98% year-over-year Second Quarter 2025 Gross profit margin increased from 45% to 47% Liquidity and Cash Flow Cash flow used in operations was $765,094 in the first six months of 2025, compared to $2,594,214 in the first six months of 2024. Cash flow used in investing activities was $15,466 for the first six months of 2025, compared to $16,390 in the first six months of 2024. Cash flow from financing activities was $746,040 in the first six months of 2025, compared to $3,597,841 in the first six months of 2024. The integration of iDoc Telehealth has been challenging yet the rewards of robust revenue growth, expanded customer relationships and operational progress should provide comfort to shareholders and interested parties alike that the Company is on the right path. The Company's is experiencing more than 100% year-over-year revenue growth which has been largely driven by the acquisition of iDoc and the growth of the Company's telehealth service. With the consolidation of VSee Lab and iDoc platforms, aligning physician coverage, service offerings, and client delivery models the Company believes both revenue growth and operational efficiencies will deliver monumental operational improvements for the near future. Finally, new clients have provided strong revenue growth and expansion into new services has improved gross margins, management is not yet satisfied and is committed to build shareholder value. "We are extremely proud of our team's execution during the exhausting acquisition process. Our growing revenue and improved operational efficiencies have laid the foundation for continued success, but we also understand that much work needs to be done to improve shareholder value. As we enter this next phase of growth, we are committed to providing products and services that will be in high demand, improve patient care, and bring efficiencies to service providers. We understand if we continue to improve our offerings the natural end result will be improved share...

Revenue: US$10.4m (up 81% from FY 2023). Net loss: US$57.7m (loss widened by US$53.9m from FY 2023). US$5.65 loss per share (further deteriorated from US$0.38 loss in FY 2023). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period VSee Health shares are down 27% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with VSee Health (at least 3 which shouldn't be ignored), and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.